These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
180 related articles for article (PubMed ID: 29620287)
1. Protein arginine N-methyltransferase 2 reverses tamoxifen resistance in breast cancer cells through suppression of ER-α36. Shen Y; Zhong J; Liu J; Liu K; Zhao J; Xu T; Zeng T; Li Z; Chen Y; Ding W; Wen G; Zu X; Cao R Oncol Rep; 2018 Jun; 39(6):2604-2612. PubMed ID: 29620287 [TBL] [Abstract][Full Text] [Related]
2. Tamoxifen resistance and metastasis of human breast cancer cells were mediated by the membrane-associated estrogen receptor ER-α36 signaling in vitro. Gu W; Dong N; Wang P; Shi C; Yang J; Wang J Cell Biol Toxicol; 2017 Apr; 33(2):183-195. PubMed ID: 27837347 [TBL] [Abstract][Full Text] [Related]
3. Estrogen receptor-α36 is involved in development of acquired tamoxifen resistance via regulating the growth status switch in breast cancer cells. Li G; Zhang J; Jin K; He K; Zheng Y; Xu X; Wang H; Wang H; Li Z; Yu X; Teng X; Cao J; Teng L Mol Oncol; 2013 Jun; 7(3):611-24. PubMed ID: 23499324 [TBL] [Abstract][Full Text] [Related]
4. Estrogen receptor-α36 is involved in pterostilbene-induced apoptosis and anti-proliferation in in vitro and in vivo breast cancer. Pan C; Hu Y; Li J; Wang Z; Huang J; Zhang S; Ding L PLoS One; 2014; 9(8):e104459. PubMed ID: 25127034 [TBL] [Abstract][Full Text] [Related]
5. ER-alpha36, a variant of ER-alpha, promotes tamoxifen agonist action in endometrial cancer cells via the MAPK/ERK and PI3K/Akt pathways. Lin SL; Yan LY; Zhang XT; Yuan J; Li M; Qiao J; Wang ZY; Sun QY PLoS One; 2010 Feb; 5(2):e9013. PubMed ID: 20126312 [TBL] [Abstract][Full Text] [Related]
6. Estrogen receptor-α variant, ER-α36, is involved in tamoxifen resistance and estrogen hypersensitivity. Zhang X; Wang ZY Endocrinology; 2013 Jun; 154(6):1990-8. PubMed ID: 23546601 [TBL] [Abstract][Full Text] [Related]
7. let-7 microRNAs induce tamoxifen sensitivity by downregulation of estrogen receptor α signaling in breast cancer. Zhao Y; Deng C; Lu W; Xiao J; Ma D; Guo M; Recker RR; Gatalica Z; Wang Z; Xiao GG Mol Med; 2011; 17(11-12):1233-41. PubMed ID: 21826373 [TBL] [Abstract][Full Text] [Related]
8. Keratinocyte growth factor (KGF) regulates estrogen receptor-alpha (ER-alpha) expression and cell apoptosis via phosphatidylinositol 3-kinase (PI3K)/Akt pathway in human breast cancer cells. Chang HL; Sugimoto Y; Liu S; Wang LS; Huang YW; Ye W; Lin YC Anticancer Res; 2009 Aug; 29(8):3195-205. PubMed ID: 19661335 [TBL] [Abstract][Full Text] [Related]
9. Expression of ER-{alpha}36, a novel variant of estrogen receptor {alpha}, and resistance to tamoxifen treatment in breast cancer. Shi L; Dong B; Li Z; Lu Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Wang Z; Xie Y J Clin Oncol; 2009 Jul; 27(21):3423-9. PubMed ID: 19487384 [TBL] [Abstract][Full Text] [Related]
10. Disruption of the ER-α36-EGFR/HER2 positive regulatory loops restores tamoxifen sensitivity in tamoxifen resistance breast cancer cells. Yin L; Zhang XT; Bian XW; Guo YM; Wang ZY PLoS One; 2014; 9(9):e107369. PubMed ID: 25203051 [TBL] [Abstract][Full Text] [Related]
11. GPR30-mediated HMGB1 upregulation in CAFs induces autophagy and tamoxifen resistance in ERα-positive breast cancer cells. Liu L; Liu S; Luo H; Chen C; Zhang X; He L; Tu G Aging (Albany NY); 2021 Jun; 13(12):16178-16197. PubMed ID: 34182538 [TBL] [Abstract][Full Text] [Related]
12. ER-α variant ER-α36 mediates antiestrogen resistance in ER-positive breast cancer stem/progenitor cells. Deng H; Yin L; Zhang XT; Liu LJ; Wang ML; Wang ZY J Steroid Biochem Mol Biol; 2014 Oct; 144 Pt B():417-26. PubMed ID: 25158023 [TBL] [Abstract][Full Text] [Related]
13. Roles of the ER-α36-EGFR/HER2 positive regulatory loops in tamoxifen resistance. Yin L; Wang ZY Steroids; 2016 Jul; 111():95-99. PubMed ID: 26884313 [TBL] [Abstract][Full Text] [Related]
14. ER-α36 mediates cisplatin resistance in breast cancer cells through EGFR/HER-2/ERK signaling pathway. Zhu L; Zou J; Zhao Y; Jiang X; Wang Y; Wang X; Chen B J Exp Clin Cancer Res; 2018 Jun; 37(1):123. PubMed ID: 29940998 [TBL] [Abstract][Full Text] [Related]
15. δEF1 down-regulates ER-α expression and confers tamoxifen resistance in breast cancer. Guo S; Li Y; Tong Q; Gu F; Zhu T; Fu L; Yang S PLoS One; 2012; 7(12):e52380. PubMed ID: 23285017 [TBL] [Abstract][Full Text] [Related]
16. CSNK1G2 differently sensitizes tamoxifen-induced decrease in PI3K/AKT/mTOR/S6K and ERK signaling according to the estrogen receptor existence in breast cancer cells. Nguyen Hoang AT; Hoe KL; Lee SJ PLoS One; 2021; 16(4):e0246264. PubMed ID: 33861751 [TBL] [Abstract][Full Text] [Related]
17. ER-α36-mediated rapid estrogen signaling positively regulates ER-positive breast cancer stem/progenitor cells. Deng H; Zhang XT; Wang ML; Zheng HY; Liu LJ; Wang ZY PLoS One; 2014; 9(2):e88034. PubMed ID: 24558373 [TBL] [Abstract][Full Text] [Related]
18. AKT3 regulates ErbB2, ErbB3 and estrogen receptor α expression and contributes to endocrine therapy resistance of ErbB2(+) breast tumor cells from Balb-neuT mice. Grabinski N; Möllmann K; Milde-Langosch K; Müller V; Schumacher U; Brandt B; Pantel K; Jücker M Cell Signal; 2014 May; 26(5):1021-9. PubMed ID: 24463007 [TBL] [Abstract][Full Text] [Related]
19. Estrogen receptor β represses Akt signaling in breast cancer cells via downregulation of HER2/HER3 and upregulation of PTEN: implications for tamoxifen sensitivity. Lindberg K; Helguero LA; Omoto Y; Gustafsson JÅ; Haldosén LA Breast Cancer Res; 2011 Apr; 13(2):R43. PubMed ID: 21492444 [TBL] [Abstract][Full Text] [Related]
20. Estrogen receptor variant ER-α36 promotes tamoxifen agonist activity in glioblastoma cells. Qu C; Ma J; Zhang Y; Han C; Huang L; Shen L; Li H; Wang X; Liu J; Zou W Cancer Sci; 2019 Jan; 110(1):221-234. PubMed ID: 30417588 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]